Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Sunshine Biopharma (SBFM) Gross Margin (2018 - 2025)

Sunshine Biopharma (SBFM) has disclosed Gross Margin for 8 consecutive years, with 32.64% as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Gross Margin fell 134.0% year-over-year to 32.64%, compared with a TTM value of 33.01% through Sep 2025, up 223.0%, and an annual FY2024 reading of 30.6%, down 402.0% over the prior year.
  • Gross Margin was 32.64% for Q3 2025 at Sunshine Biopharma, down from 36.37% in the prior quarter.
  • Across five years, Gross Margin topped out at 64.98% in Q2 2021 and bottomed at 25.33% in Q2 2024.
  • Average Gross Margin over 5 years is 39.98%, with a median of 35.12% recorded in 2023.
  • The sharpest move saw Gross Margin crashed -3465bps in 2021, then skyrocketed 1105bps in 2025.
  • Year by year, Gross Margin stood at 28.0% in 2021, then skyrocketed by 35bps to 37.85% in 2022, then dropped by -12bps to 33.44% in 2023, then dropped by -4bps to 32.24% in 2024, then rose by 1bps to 32.64% in 2025.
  • Business Quant data shows Gross Margin for SBFM at 32.64% in Q3 2025, 36.37% in Q2 2025, and 30.67% in Q1 2025.